Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PD Controller: Design01:26

PD Controller: Design

673
In automotive engineering, car suspension systems often employ Proportional Derivative (PD) controllers to enhance performance. PD controllers are utilized to adjust the damping force in response to road conditions. A controller, acting as an amplifier with a constant gain, demonstrates proportional control, with output directly mirroring input.
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
673
Time-Domain Interpretation of PD Control01:07

Time-Domain Interpretation of PD Control

411
Proportional-Derivative (PD) control is a widely used control method in various engineering systems to enhance stability and performance. In a system with only proportional control, common issues include high maximum overshoot and oscillation, observed in both the error signal and its rate of change. This behavior can be divided into three distinct phases: initial overshoot, subsequent undershoot, and gradual stabilization.
Consider the example of control of motor torque. Initially, a positive...
411
Frequency-Domain Interpretation of PD Control01:24

Frequency-Domain Interpretation of PD Control

394
Proportional-Derivative (PD) controllers are widely used in fan control systems to improve stability and performance. A fan control system can be effectively represented using a Bode plot to illustrate the impact of a PD controller through its transfer function. The Bode plot visually conveys how PD control modifies the fan's response across various frequencies, providing a frequency domain interpretation of the controller's behavior.
The proportional control gain, combined with the...
394
Neuromuscular Junction And Blockade01:29

Neuromuscular Junction And Blockade

5.1K
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
5.1K
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

16
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
16
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

2.3K
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

Journal for immunotherapy of cancer·2026
Same author

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

JCO oncology practice·2026
Same author

Clinical Characteristics and Management of Immune Checkpoint Inhibitor-Associated Sicca Syndrome.

Cancers·2026
Same author

A Multidisciplinary Approach to Checkpoint Inhibitor Adverse Reactions.

The journal of allergy and clinical immunology. In practice·2026
Same author

A retrospective pharmacovigilance analysis based on the FAERS database reveals sex-associated differences in toxicities of CAR T-cell therapy.

Nature communications·2026
Same author

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Journal for immunotherapy of cancer·2026

Related Experiment Video

Updated: Feb 15, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K

Toxicities Associated With PD-1/PD-L1 Blockade.

Daniel Y Wang1, Douglas B Johnson, Elizabeth J Davis

  • 1From the Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN.

Cancer Journal (Sudbury, Mass.)
|January 24, 2018
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors targeting PD-1/PD-L1 offer durable cancer responses but can cause autoimmune-like side effects. Management involves immune suppression, mainly with corticosteroids.

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K

Related Experiment Videos

Last Updated: Feb 15, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K

Area of Science:

  • Oncology
  • Immunology
  • Pathology

Background:

  • Immune checkpoint inhibitors (ICIs), especially PD-1/PD-L1 blockers, yield durable responses in diverse cancers.
  • While generally safe, ICIs can trigger autoimmune-like toxicities affecting multiple organ systems.

Purpose of the Study:

  • To review the mechanisms of immune-related adverse events (irAEs).
  • To outline the clinical and pathological features of major toxicities from PD-1/PD-L1 blockade.
  • To summarize current management strategies for irAEs.

Main Methods:

  • Literature review of immune checkpoint inhibitor mechanisms.
  • Analysis of clinical and pathological data on irAEs.
  • Synthesis of management guidelines for irAEs.

Main Results:

  • PD-1/PD-L1 blockade can lead to a wide range of irAEs.
  • Understanding irAE mechanisms is crucial for effective management.
  • Corticosteroids are a primary treatment for ICI-induced toxicities.

Conclusions:

  • PD-1/PD-L1 inhibitors are effective cancer treatments but require careful monitoring for irAEs.
  • Prompt recognition and management of irAEs are essential for patient safety.
  • Immune suppression, particularly corticosteroids, is key in managing these toxicities.